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Abstract 
 Variables impacting the formation of b2 ions along the “diketopiperazine” pathway are 
explored using IRMPD action spectroscopy and gas-phase hydrogen-deuterium exchange for a 
series of QAXIG and NAXIG pentapeptide analogues. The b2 ion is a unique fragment in peptide 
fragmentation because it can be one of two main isobaric structures, the diketopiperazine or the 
oxazolone. The formation of these has been thought to be largely governed by the identity of the 
first two residues at the N-terminus of the peptide. We show here that a basic residue is not 
required for the formation of the diketopiperazine structure, as the amide side chain of a 
glutamine or asparagine residue is implicated in the formation of this structure. Furthermore, the 
length of the peptide and identity of the third residue of the peptide is shown for the first time to 
influence the diketopiperazine:oxazolone ratio.  
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Introduction 
The details of gas phase peptide fragmentation pose an intriguing challenge both 
fundamentally and practically. The chemistry inherent to mass spectrometry fragmentation is 
incompletely understood and solution and gas phase molecules can exhibit very different 
behaviors.1-2  Peptides are an ideal medium with which gas phase chemistries can be explored.  
Solid phase FMOC and BOC-based chemistries permit peptides to be synthesized in an almost 
unlimited number of motifs and functionalities, allowing fragmentation chemists to design 
custom systems and isolate desired phenomena. Practically, understanding peptide fragmentation 
is of high interest in the field of proteomics, wherein mass spectrometry and tandem mass 
spectrometry have become invaluable tools. In a proteomics experiment, tandem mass spectra 
are collected so that peptide sequences can be assigned from the fragmentation pattern of the 
precursor, inferring protein identifications. Because a single proteomics experiment typically 
generates thousands of spectra, interpretation and sequence assignment has been relegated to the 
domain of sequencing algorithm interpretation programs such as MASCOT and SEQUEST.3-5 
These algorithms are based on the understanding of peptide fragmentation, but tend to use 
simplistic fragmentation models to assign spectra. 
As the ratio of assigned sequences to generated spectra remains modest at best, a number 
of strategies are being developed to improve both spectral quality, algorithm efficiency, and 
database approaches. While the more popular algorithms often trade processing speed for model 
complexity, a new trend is emerging to develop programs that incorporate non-standard 
fragmentation pathways and ion intensity into the algorithm.6-8  Fundamental experiments 
continue to increase the understanding of the enhancement and suppression of fragmentation at 
particular residues and this understanding adds confidence to sequence assignments. Omission of 
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ion intensity in these routines, as is often done, forfeits the increased confidence in the sequence 
assignment. Further development of algorithms along these lines will demand a more thorough 
understanding of fragmentation behavior, as the chemistry that governs the variations in ion 
intensity is still only partially understood.  
 The standard fragmentation pathway of protonated peptides by CID occurs at the 
backbone amide bond, generating a series of “b” and “y” type ions, wherein the C-terminal 
fragment or y ion is a truncated peptide and the N-terminal portion forms a cyclic structure. 
Yalcin and co-workers first proposed a 5-membered oxazolone ring as the dominant b ion 
structure using kinetic energy release data; this structure was later confirmed using a 
combination of computational modeling and action IRMPD spectroscopy by Polfer and co-
workers.9-13  Later studies using action IRMPD and hydrogen-deuterium exchange (HDX) on 
YGGFL, YAGFL, and oligoglycine provided evidence for low abundance macrocyclic structures 
in b ion populations.14-16 These structures are able to rearrange into a number of oxazolone 
structures, effectively scrambling the sequence of the peptide. For this reason, they received 
much attention over subsequent years.16-24   
The smallest of these cyclic peptide structures, the b2 diketopiperazine, has been 
particularly well-studied, not because of its role in sequence scrambling, but rather because it 
requires an unusual trans-cis isomerization step prior to its formation.25-26 This isomerization step 
adds an interesting chemical feature unique to the b2 ion: although the diketopiperazine is 
typically thermodynamically more stable, trans-cis isomerization adds a kinetic barrier to the 
formation of diketopiperazine.27-28 The typical result is an interplay in which the thermodynamic 
(diketopiperazine) and kinetic product (oxazolone) are variably formed, although the kinetic 
pathway is typically followed in CID experiments. However, a number of studies have shown 
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that residue identity plays an influential role in favoring or disfavoring these pathways. Wysocki 
and coworkers have shown evidence indicating that the diketopiperazine structure is present in 
low abundance for the AP, IP, and VP systems, concluding that the more cis character of the 
proline amide bond makes diketopiperazine formation more favorable.29-32 A vast body of work 
has gone into histidine containing b2 systems, and it has been shown that HA, AH, HG, and GH 
all form mixtures of diketopiperazine and oxazolone structures while HP forms exclusively 
diketopiperazine.26,33-34  The Polfer lab has recently demonstrated that an arginine residue in the 
first or second position also makes diketopiperazine formation competitive in b2-H20 ions.35 
Although b2 ions that contain only aliphatic and aromatic residues have been shown to feature 
exclusively oxazolone structures,36-38 a basic residue in residue positions 1 or 2 has been shown 
to allow trans-cis isomerization and diketopiperazine formation.33,35  
 In this paper we explore the effects of N-terminal glutamine or asparagine and a variable 
third residue in pentapeptide systems on diketopiperazine and oxazolone formation using a 
combination of HDX and action IRMPD spectroscopy. Being non-basic, glutamine and 
asparagine are not capable of sequestering the mobile proton as well as a basic residue, but both 
possess an amide side chain with varying lengths that permit a variety of proton bridging 
chemistries. The impact of the remaining peptide chain on the formation of b2 ions has largely 
been disregarded in studies of b2 ions. In this study, systems of sequence QAXIG and NAXIG, 
with the third residue being either an acidic residue (glutamic or aspartic acid) or an aliphatic 
residue (leucine) are examined using action IRMPD spectroscopy and gas-phase 
hydrogen/deuterium exchange. Acidic residues were selected in order to study the effect of a 
flexible and reactive side chain at the third position while simultaneously avoiding conflicting 
data arising from usage of a basic residue such as histidine or lysine. A pentapeptide scaffold 
Print to PDF without this message by purchasing novaPDF (http://www.novapdf.com/)
was additionally chosen in order to more accurately examine the behavior of longer peptides 
typically observed in proteomics experiments.  
Material and Methods 
Peptide synthesis 
 FMOC protected amino acids were obtained from Novabiochem (San Diego, CA) and 
peptides were synthesized in-house using standard FMOC solid phase synthesis techniques.39 
The C-terminal, resin-linked residue was used without purification and treated with 
dimethylformamide (DMF) to swell the polymer bead. The FMOC protecting group was 
removed from the growing peptide by washing with 70:30 DMF:piperidine solvent. Coupling 
was performed in a stepwise manner using -benzotriazole-N,N,N’,N’-tetramethyl-uronium-
hexafluoro-phosphate (HBtU) and N,N-diisopropylethylamine (DIEA) to promote formation of 
the amide bond. Peptides were cleaved from the resin by incubation in 95% trifluoracetic acid 
and were extracted twice with diethyl ether. Purified peptides were then diluted into 50:50:0.1% 
Acetonitrile:H20:formic acid electrospray solvent before introduction into the mass spectrometer.  
Mass spectrometry 
 Deuterated ammonia was used for all gas-phase hydrogen/deuterium exchange (HDX) 
studies and was obtained from Sigma-Aldrich (St. Louis, MO). Fragmentation and 
hydrogen/deuterium exchange studies were performed on a Thermo Scientific Velos Pro dual 
linear ion trap. Following introduction to the gas phase by an electrospray source, precursor ions 
were monoisotopically mass selected in high pressure region of the trap and fragmented by HCD 
to generate the b2 ions. Gas-phase hydrogen/deuterium exchange (HDX) was performed by 
saturating the trap with deuterated ammonia and subsequently flushing with helium to generate a 
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low ambient pressure of deuterated ammonia that remained relatively constant for several 
minutes. The exchange of leucine-enkephalin for 10ms was used to monitor this pressure and 
incubation of the analyte b2 ions was performed in triplicate in all experiments for 2 minute 
intervals using a deuterated ammonia pressure that resulted in 5% exchange of leucine-
enkephalin.  
 Action IRMPD spectroscopy was performed using a trapping mass spectrometer coupled 
to a free electron laser at the CLIO facility in Orsay, France. Ions were introduced to the gas 
phase using electrospray ionization and protonated precursor molecules transmitted to the ion 
trap for CID and IRMPD. A Bruker Daltonics Esquire 3000+ ion trap was used coupled to a free 
electron laser was used for QAXIG experiments and a Bruker Daltonics 7T FT-ICR was used for 
NAXIG peptides. QAXIG precursor ions were mass selected and fragmented within the ion trap 
to generate b2 ions and NAXIG b2 ions were generated by quadrupole CID prior to entering the 
ICR cell. Once generated, b2 ions were subjected to 110 ms macropulses of irradiation from the 
free electron laser, each of which was comprised of 12, nanosecond timescale micropulses. 
Typical laser energies were 450-600 mW. Following macropulse irradiation, fragment and 
precursor ions were detected using was ion trap or FT-ICR analyzers. Single spectra were 
acquired for NAXIG peptides and duplicate spectra for QAA and QAXIG peptides. Spectra were 
generated by plotting the fragmentation efficiency of the b2 ion against irradiation frequency.  
Computations 
 Optimizations and frequency calculation were performed using the Gaussian 09 software 
package with a B3LYP/6-311++G** basis set. Preliminary conformations of oxazolone and 
diketopiperazine structures were obtained using a conformation search function within the 
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Macromodel software package.40 Collections of conformations were generated for both the 
diketopiperazine and oxazolone classes of molecules, considering all amine nitrogens and amide 
oxygens as potential protonation sites. Redundant conformers were eliminated at the B3LYP/6-
31G level if they shared identical bridging with another conformer and were greater than 12 
kcal/mol higher in energy than the lowest energy conformer. Final frequency spectra were scaled 
by 0.978 and the full-width at half-maximum peak width adjusted to 10 cm-1 to best correlate 
with experimental spectra.  
Results 
Comparison of NAA and NAXIG systems 
Systems featuring an N-terminal asparagine or glutamine have been shown previously by 
Stein and coworkers to fragment via abundant water and ammonia loss pathways.41-42 The 
fragmentation behavior of the NAEIG b2 ion by CID is consistent with their findings (Figure 
S1(a)). The b2 ion shows dominant fragment ion peaks at m/z 169 (-NH3), 168 (-H20), 158 (-
CO), 141 (-CO-NH3), and 140 (-CO-H20) representative of two major fragmentation pathways: 
water/ammonia loss, CO loss to form the a2 ion, and a combination of the two.  
Action IRMPD spectroscopy was obtained for the b2 ion from peptide analogues of 
sequence NAA and NAXIG, wherein X was glutamic acid, aspartic acid, or leucine. The NAXIG 
b2 ion action IRMPD spectra are shown in Figure 5 (a) – (c). The IRMPD spectrum for the b2 ion 
of NAA is shown in Figure 5(d) and is in excellent agreement with the calculated IR spectrum of 
the ring protonated oxazolone structure shown in Figure 5(f).  From inspection of the four 
experimental IRMPD spectra in Figure 5 (a)-(d), clear differences in the b2 absorption behavior 
are evident in the 1500-2000 cm-1 range. The b2 ions from both NAEIG and NADIG exhibit 
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dominant absorption bands at 1420, 1600, and 1750 cm-1 while the b2 population from NAA 
features dominant absorption bands at 1610 and 1690, as well as a weak band at 1900, that 
corresponds to a ring carbonyl stretching mode and is diagnostic of an oxazolone structure. Laser 
power in this range is extremely weak and this band typically appears lower in intensity than 
predicted by DFT calculations. The b2 population from NALIG exhibits absorption modes 
consistent with both the NAA and NA(D/E)IG type spectra, suggesting that it is composed of a 
mixture of structures.  
The diagnostic absorption bands at 1420, 1600, and 1750 cm-1 exhibited by the b2 ions 
from NADIG and NAEIG are in relatively good agreement with the amide stretching modes of 
the carbonyl protonated diketopiperazine structure shown in Figure 5(e), although the calculated 
band at 1750 cm-1 is blue shifted by 10 cm-1 relative to the experimental band. The lowest energy 
diketopiperazine structure for this system has the charging proton participating in a hydrogen 
bond between the asparagine backbone carbonyl oxygen and the side chain carbonyl oxygen. 
The DFT calculated spectrum for this structure is an exceptionally poor match to the 
experimental and was therefore discarded. It is shown in Supplementary Information Figure S2 
in comparison to the experimental NAXIG spectra. The second lowest diketopiperazine structure 
has the charging proton located on the alanine carbonyl oxygen and is 8 kcal/mol higher in 
energy than the lowest energy diketopiperazine structure. This diketopiperazine structure is, 
however, 5 kcal/mol lower in energy than the lowest energy oxazolone structure. The amide 
stretching mode at 1780 cm-1 predicted by DFT calculations is seen to be in excellent agreement 
with the experimental NA(D/E)IG b2 spectra. Although the placement of the predicted bands at 
1600 and 1690 cm-1 are in agreement with the experimental NADIG and NAEIG b2 spectra, the 
relative intensity of these bands are do not agree well with the experimental spectrum.  However, 
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poor agreement of theoretical and experimental band intensities has been observed frequently in 
action IRMPD experiments.35,43-45  For example, the predicted NH2 scissoring mode at 1600 cm-1 
is anticipated by DFT to be very weak, but appears as one of the strongest bands in the 
experimental spectrum.  We have observed highly intense NH2 scissoring modes in our studies 
of other peptide systems.33,46 The b2 ion populations from NAEIG and NADIG thus appear to be 
exclusively diketopiperazine and are the first evidence showing a non-basic residue in one of the 
first two residue positions (asparagine) contributing to dominant diketopiperazine formation.  
The dominant absorption bands for the b2 ions of NAEIG and NADIG are in clear 
contrast with the diagnostic oxazolone stretching modes at 1620 and 1690 cm-1 observed in the 
NAA b2 ion spectrum. The NALIG spectrum appears as a composite of the NA(E/D)IG and 
NAA b2 experimental spectra, with bands at 1420, 1600, 1690, and 1750 cm-1, suggesting a 
roughly equal mixture of diketopiperazine and oxazolone structures. These results unequivocally 
demonstrate that the length and structural composition of the precursor peptide impacts the type 
of b2 ion formed. However, because the NAA precursor varies both in peptide length and side 
chain identity of the third residue, it is not possible to attribute the presence of diketopiperazine 
b2 in the NALIG system to either variable alone. The trend for the acidic amino acid systems, 
however, is very clear: the acidic residue in the third position causes the diketopiperazine 
structure to be exclusively favored.  
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 Figure 1: Action IRMPD spectra from the b2 ion of a) NAEIG, b) NADIG, c) NALIG, and d) 
NAA. The theoretical IR spectra for the second lowest energy diketopiperazine and lowest 
energy oxazolone structures are shown in (e) and (f) respectively.  
Glutamine-containing systems: QAXIG 
 Figure 2 shows a comparison of the action IRMPD spectra of the b2 ions from the (a) 
QALIG, (b) QADIG, and (c) QAEIG peptide analogues. The range from 1000 to 2000 cm-1 can 
be seen to be complex with intense bands at 1610, 1670, 1780, and 1900 cm-1. Dominant bands a 
t 1610 and 1788 cm-1 are present in all spectra and suggest all three analogues share, in part, a 
common b2 structure. However, the bands at 1670 and 1900 cm-1 are prominent only in the 
QADIG b2 spectrum and suggest the presence of a second structure for this analogue. As before, 
the appearance of a band at 1900 cm-1 suggests that this second structure is an oxazolone. A 
small peak at 1670 cm-1 is present in the QALIG spectrum suggests small amounts of oxazolone 
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are present in this system. The absence of the 1900cm-1 peak in this spectrum can be attributed to 
a combination of low FEL laser power in this range and the low abundance of the oxazolone 
population.  
 
Figure 2: Action IRMPD spectra of the b2 ions from (a) QALIG, (b) QADIG, and (c) QAEIG. 
Bands at 1670 and 1900 cm-1 suggest and oxazolone structure is present in the QALIG and 
QADIG b2 populations.  
Computational modeling of the QA oxazolone and diketopiperazine b2 structures was 
performed in order to better interpret the spectra shown in Figure 2. Figure 3 shows a 
comparison between the experimental QADIG action IRMPD spectrum and theoretical 
oxazolone and diketopiperazine structures. In the lowest energy diketopiperazine structure, the 
charging proton is bound between the side chain amide oxygen and the proximal 
diketopiperazine carbonyl oxygen. Due to the flexibility of the glutamine side chain, several 
conformations are accessible to this structure. The theoretical IR spectra for the two most stable 
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conformations are shown in Figure 3(a) and (b) and make it apparent that movement of this side 
chain has a profound impact on the absorption spectrum of the molecule. For this reason, it is not 
possible to assign the experimental spectrum to a single conformer of this diketopiperazine 
structure. However, Figure 3(c) shows an empirical overlay composed of 70% diketo B and 30% 
diketo A that shows relatively good agreement with the bands at 1610 and 1780 cm-1. The 
experimental spectrum features several bands between 1400 and 1600 cm-1 that are more 
coalesced than theory predicts, but small red or blue shifts due to coupling could account for 
these deviations. Comparison of the experimental spectrum with the theoretical oxazolone 
spectrum shows good agreement of the bands at 1670 and 1900 cm-1 with the oxazolone amide 
and ring carbonyl stretching modes and confirms the presence of the oxazolone structure in the 
QADIG b2 population. Thus, the QADIG b2 ion population is a mixture of carbonyl protonated 
diketopiperazine and N-terminally protonated oxazolone structures.  
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Figure 3: The two lowest energy diketopiperazine conformations are shown in (a) and (b), an 
empirical combination of (a) and (b) is shown in (c), and the N-terminally protonated oxazolone 
is shown in (d). The experimental action IRMPD spectrum of the b2 of QADIG is overlaid in 
hashed lines over all four theoretical spectra.  
 Extrapolation of the comparison between the experimental QADIG b2 and theoretical 
oxazolone and diketopiperazine in Figure 3 to the experimental QAXIG spectra in Figure 2 
suggests that the dominant QA b2 structure is the diketopiperazine. Although it is difficult to 
quantify the relative population abundances by action IRMPD, it is evident that both QALIG and 
QADIG feature some amount of oxazolone, although it is of low abundance in the QALIG case. 
In order to enumerate the relative abundances of the two populations, hydrogen-deuterium 
exchange studies were performed and are described in detail below. It is clear, however, that 
despite the chemical similarity between glutamic and aspartic acid, the effect they have on the 
diketopiperazine: oxazolone ratio is profoundly different in the QAXIG systems. As both 
NADIG and NAEIG formed exclusively diketopiperazine in the NAXIG systems, the disparity 
between QADIG and NADIG suggests that the amide side chain plays a significant role in the 
oxazolone and diketopiperazine pathways. Moreover, these data suggest that the interactions in 
which the amide side chain can participate are highly dependent on the length of the side chain.  
The potential energy surfaces of the Q/NAXIG analogues are extremely complex and numerous 
pathways can lead to the oxazolone and diketopiperazine structures. Thus, additional systems 
need to be evaluated in order to better characterize this behavior. 
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Action IRMPD Comparisons between NAXIG and QAXIG systems  
Despite the somewhat poor quality of the match of the experimental QA b2 ion spectra 
with the DFT predicted diketopiperazine spectrum, comparison with NAXIG systems strongly 
supports the diketopiperazine assignment. The diagnostic diketopiperazine NH2 scissoring and 
amide stretching modes that appear at 1600 and 1750 cm-1 in the NAXIG systems are blue 
shifted to 1610 and 1780 cm-1 in the QAXIG systems, but the relative ratios of these bands 
remains the same. The blue shift can be attributed to the diketopiperazine structures for the NA 
and QA systems having different protonation sites. In the QA diketopiperazine, the charging 
proton is located in a hydrogen bond between the glutamine backbone carbonyl oxygen and side 
chain carbonyl oxygen.  In contrast, in the NA diketopiperazine, the charging proton is located 
on the alanine carbonyl oxygen. This is particularly interesting as this is not the lowest energy 
diketopiperazine structure. While this is unusual, it can readily be attributed to the relatively 
short asparagine side chain. Upon closure of the diketopiperazine ring, the mobile proton 
becomes one of the protons on what was formerly the N-terminus. Because proton transfer in the 
gas phase relies on chains of basic sites between which protons can “hop,” the asparagine side 
chain must mediate transfer of the charging proton to the other side of the molecule due to the 
lack of intermediate basic sites. It is plausible that the length of the side chain may limit the 
extent to which it can perform this operation, causing the charging proton to be transported to the 
nearest basic site, the alanine carbonyl oxygen.  
Hydrogen-deuterium exchange studies 
Gas phase HDX was performed on the NAXIG and NAA peptide analogues following 
activation of the precursor at various collision energies in order to evaluate the influence of 
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energy on the formation of the diketopiperazine and oxazolone NA b2 structures. For simplicity, 
this technique will be referred to as energy resolved HDX or ERHDX. The exchange 
distributions from these experiments are shown in Figure 4. All b2 ions were incubated in 
deuterated ammonia for 500 ms, as this time features the strongest difference in oxazolone and 
diketopiperazine exchange behavior (see Supplementary Information, Figure S3).  The b2 
generated via 4% activation of the NAA peptide (see Figure 4a), demonstrated to be dominantly 
oxazolone in action IRMPD experiments, exhibits an exchange pattern in which the dominant 
product incorporates three deuteriums into the molecule after 500 ms incubation with the 
deuterating reagent. At higher collision energies, the relative intensity of the D0, D1, and D2 
peaks rises to some extent, although the D3 remains the dominant peak in the distribution. The 
rise of these peaks may be related to the appearance of a second population at higher activation 
energies. In stark contrast to the HDX distribution observed for the b2 ion from NAA, the b2 
populations of NADIG and NAEIG (Figure 4 c and d) feature much slower hydrogen-deuterium 
exchange, with the dominant peak in the exchange distribution being the D0 at all collision 
energies.  The bimodal distribution observed for the b2 ion from NALIG suggests that it is 
composed of a mixture of a less extensively and more extensively exchanging population. 
Interestingly, the more extensively exchanging population is observed to increase in relative 
abundance at higher collision energies.  
In order to assign structures to the different distributions observed by HDX, the basicity 
of the functional groups of the diketopiperazine and oxazolone structures must be considered.   
The diketopiperazine structure features three amide functional groups, with 4 exchangeable 
protons on amide nitrogens and the charging proton located on amide oxygen.  Because amide 
groups are non-basic, exchange with deuterated ammonia is predicted to be very slow. In 
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contrast, the oxazolone b2 structure is composed of a side chain amide, a primary amine, and a 
ring imine functional group. The ring protonated oxazolone contains 2 exchangeable protons on 
the primary amine (N-terminus) and one on the ring imine, all of which would be expected to 
exchange rapidly with ammonia due to their similar gas phase basicity. Moreover, gas phase 
HDX-ECD experiments have shown that backbone amide groups exchange more slowly with 
ND3 than the basic side chains and peptide termini.47 Thus, the more extensively exchanging 
structure can be assigned to be the oxazolone and the less extensively exchanging structure the 
diketopiperazine. Although HDX does not directly show structure, in conjunction with action 
IRMPD measurements, in which NAA exclusively formed an oxazolone b2, NAEIG and NADIG 
formed exclusively diketopiperazine b2 ions, and NALIG formed a mixture, assignment of the 
less extensively and more extensively populations as diketopiperazine and oxazolone, 
respectively, is reasonable. In addition, our group has observed this trend in the HDX behavior of 
several oxazolone and diketopiperazine structures.26,32,48 
From DFT modeling, the lowest energy diketopiperazine structure has the charging 
proton located in a hydrogen bond between the side chain amide oxygen and the alanine amide 
oxygen. However, the predicted IR spectrum for this structure is a particularly poor match with 
the experimental action IRMPD b2 spectrum from NADIG and NAEIG. The second lowest 
energy structure, however, shows good agreement with the experimental action IRMPD spectra 
of the b2 of NADIG and NAEIG. This structure features the charging proton localized on the 
asparagine backbone amide oxygen. This structure is 5 kcal/mol lower in energy than the most 
stable oxazolone structure (ring protonated). As action IRMPD spectroscopy of the NAXIG 
analogues shows no evidence for the different precursors producing oxazolone and 
diketopiperazine b2 ions of differing protonation sites, the NA b2 ions will have these same 
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oxazolone and diketopiperazine energies regardless of precursor.  Thus, the differences in b2 
structure observed by HDX and action IRMPD for the NAA and NAXIG analogues can be 
attributed to variable ring closure and trans-cis isomerization barriers that may change depending 
on precursor structure. This suggests that the trans-cis isomerization and diketopiperazine ring 
closure events in the NAA system must have significantly higher energy transition states than 
does the oxazolone ring closure transition state. Thus, the lower energy diketopiperazine 
structure would not form at low energies and would only form to a small extent at higher 
energies, as is observed for the NAA b2. As noted above, Armentrout and Paizs have shown that 
the barrier for diketopiperazine ring closure in the GG and GGG systems is significantly higher 
than the oxazolone ring closure barrier, which is consistent with this behavior.  
The b2 oxazolone structure does not form for the NADIG and NAEIG analogues, 
suggesting that trans-cis isomerization and diketopiperazine ring closure barriers are much lower 
in energy than the oxazolone ring closure barrier for these analogues. The NALIG system is 
perhaps the most interesting of the NAXIG analogues, as variable amounts of oxazolone and 
diketopiperazine form depending on the activation energy used to generate the b2. At low 
energies, the diketopiperazine is favored, whereas the higher energies favor the oxazolone 
structure. This trend is somewhat counter-intuitive because computational studies performed by 
Armentrout and Paizs, in which it was shown that the diketopiperazine has a significantly higher 
ring closure barrier than does the oxazolone structure, would suggest that the thermodynamic 
product would form more abundantly at higher energies.28,49 One explanation for this behavior is 
that the oxazolone has a higher ring closure barrier but also a higher density of states. Thus, at 
low energies, the lower energy pathway is favored, whereas at higher energies the oxazolone ring 
closure transition state is more populated, causing the oxazolone to form with higher abundance.  
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Figure 6 shows a diagram in which the ring closure barriers are predicted based on these 
experiments. The density of states explanation for this behavior suggests that degrees of freedom 
in the bridging conformations of the oxazolone and diketopiperazine ring closure transition states 
may be a critical factor in discriminating which b2 structure forms in N-terminal asparagine 
systems.  
 
Figure 4: HDX of the b2 population of NAA (a), NALIG (b), NADIG (c), and NAEIG (d) 
analogues following generation by HCD at various collision energies. 
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 Figure 5: Diagram showing estimated ring closure barriers for the formation of oxazolone and 
diketopiperazine b2 ion structures for (a) NAA and (b) NALIG based on ERHDX data and 
computational modeling of NA b2 oxazolone and diketopiperazine structures.  
ERHDX was performed on the QAA, QALIG, QADIG, and QAEIG analogues and 
results are shown in Figure 6.  Because of the low abundance of the b2 ion from the QAA 
system, acquisition of an action IRMPD spectrum of this b2 ion was not feasible, however, it was 
possible to obtain HDX. As with the NAA system, the HDX of the b2 from QAA features rapid 
exchange in which three exchanges dominate after 500 ms, suggesting QAA forms an oxazolone 
b2 structure. Computational modeling of the QA oxazolone and QA diketopiperazine indicates 
that the lowest energy oxazolone (N-terminally protonated) is 10.6 kcal/mol higher in energy 
than the lowest energy diketopiperazine. However, the exchange distribution of the QAA b2 does 
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not reflect a change in b2 population over energy, as the distribution appears relatively constant 
over the energy range studied. The constancy of this pattern over a range of energies suggests 
that the barrier for diketopiperazine ring closure is significantly higher than the oxazolone ring 
closure barrier in this system. The pattern using 28% HCD energy appears somewhat different 
from the other energy points, with the distribution centering on the D1 peak; however, the 
relative abundance of the b2 at this energy is less than 1% and the low signal to noise ratio of the 
peak may contribute to the unusual oxazolone distribution.   
Based on ERHDX, the b2 population from all of the QAXIG analogues is a clear mixture 
of two structures, presumably oxazolone and diketopiperazine, across all energies. The behavior 
of these systems at low energies agrees well with action IRMPD data, where QALIG and 
QAEIG form a dominant diketopiperazine b2 and QADIG generates a more even mixture of 
oxazolone and diketopiperazine. However, ERHDX suggests that the b2 population from QALIG 
and QAEIG both shift to a dominant oxazolone population at high collision energies. This 
behavior is similar to that observed in the NALIG system, and may again be related to the 
density of states in the oxazolone and diketopiperazine ring closure transition states. In contrast, 
however, the b2 population from QADIG can be seen to shift very little by ERHDX, although 
small increases in diketopiperazine are observed with increasing collision energy. A 
comprehensive computational study is needed to elucidate the structural details of the precursor 
peptides, the heights of these barriers, and the transition state structures, but such a study is 
computationally expensive and beyond the scope of this paper. Nonetheless, ERHDX of the 
(Q/N)AXIG and (Q/N)AA analogues demonstrates that peptides with an N-terminal amide 
residue feature b2 oxazolone and diketopiperazine ring closure barriers that are exceptionally 
close in energy. Moreover, the relative abundance of the diketopiperazine and oxazolone b2 
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structures can be altered by manipulation of the chemistry of the first and third residue and the 
length of the peptide.  
 
Figure 6: HDX of the b2 population of QAA, QALIG, QADIG, and QAEIG analogues following 
generation by HCD at various collision energies.   
 Figure 7 shows the relative diketopiperazine abundance following activation over a range 
of energies for the NAXIG, QAXIG, QAA, and NAA systems. Population abundances were 
calculated using the ratio of the D0 and D3 peaks in the HDX distribution of each system. 
Because the presumed oxazolone population is centered at D3 and the presumed diketopiperazine 
at D0, this method gives a semi-quantitative approximation of the population abundance of each 
structure.  Inspection of the plot shows that the diketopiperazine structure is ubiquitous in the 
(Q/N)AXIG systems. Only in the tripeptides (NAA and QAA) is the b2 oxazolone dominant 
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across the energy series. None of the pentapeptide analogues forms exclusively oxazolone, 
although the fragmentation pathways followed by the NALIG, QALIG, and QAEIG analogues 
are observed to dramatically change as a function of collision energy. Only in the QADIG 
system does a mixture of oxazolone and diketopiperazine form and remain constant across the 
energy series. Although the formation of diketopiperazine and oxazolone type structures is 
competitive in this system, it is not obvious why. In the NAXIG series, the presence of an acidic 
third residue caused the diketopiperazine structure to be exclusively favored, but this trend is not 
present for the QAXIG systems, where increased collision energy increases the relative 
abundance of the oxazolone population for both QALIG and QAEIG. Density functional theory 
calculations confirm that the diketopiperazine structure is the thermodynamically favored 
product, but further investigation is necessary in order to probe the involvement of the amide and 
acid side chains in trans-cis isomerization and ring closure. Additional experimental studies are 
necessary to fully probe the effect of first position amide side chains and third position acid side 
chains.  
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 Figure 7: Relative b2 diketopiperazine population abundance using 4%, 12%, 20%, and 28% 
HCD collision energy to generate b2 from (Q/N)AXIG and (Q/N)AA analogues. Population 
abundances are roughly calculated based on the ratio of D0 and D3 in the ERHDX spectra.  
Conclusions 
 Dominant diketopiperazine b2 ion formation is demonstrated for the first time in amide-
side chain containing systems. The non-basic side chain of glutamine and asparagine promotes 
diketopiperazine formation in pentapeptides of sequence (N/Q)AXIG. The identity of the third 
residue is additionally shown for the first time to be a factor in the preference for oxazolone vs. 
diketopiperazine formation. Leucine in the third position generates the greatest proportion of 
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oxazolone b2 in both Q and N analogues, particularly at high collision energies, while aspartic 
acid in this position yields an almost exclusive b2 diketopiperazine population in NADIG and a 
more dominant diketopiperazine population in QADIG. In contrast, the oxazolone predominantly 
forms in the QAA and NAA systems, suggesting that the length of the peptide may also be a 
factor in diketopiperazine vs. oxazolone formation. That oxazolone formation is more abundant 
in the leucine containing systems while diketopiperazine formation is more abundant in the 
aspartic acid containing systems may be related to either the hydrophobicity and steric bulk of 
the third position side chain or the bridging interactions in which both the acid and amide side 
chains can participate.  A systematic study varying the length and chemical identity of the first 
and third residues and more extensive modeling of transition states is necessary in order to better 
understand the mechanistic details of this behavior.  
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